Skip to main content

Table 1 Characteristics of included randomized controlled trials

From: Choices in fluid type and volume during resuscitation: impact on patient outcomes

Trial N Population Type of fluid Outcomes Conclusion
Intervention N Control N
Myburgh 2012 (CHEST) 6,651 ICU patients 6% HES (130/0.4) 3,315 Saline 3,336 90-day mortality, AKI, RRT No mortality difference; increased AKI and RRT use with HES
Perner 2012 798 ICU patients with severe sepsis 6% HES (130.0.42) 398 Ringer’s acetate 400 90-day mortality, RRT Increased 90-day mortality with HES; increased use of RRT with HES
Yates 2013 202 Medium to high risk elective colorectal surgery patients 6% HES (130/0.4) 104 Hartmann’s solution 98 Day 5 post-op GI morbidity; post-op complications, LOS, coagulation and inflammation No difference in any of the measured outcomes
Annane 2013 (CRISTAL) 2,857 ICU patients with hypovolemic shock Colloids (gelatins, dextrans, HES, 4% or 20% albumin) 1,414 Crystalloids (isotonic or hypertonic saline, Ringer’s lactate) 1,443 28- and 90-day mortality; days alive without the need for RRT, MV, or vasopressors No difference in 28-day mortality; 90-day mortality lower in colloid group
Caironi 2014 (ALBIOS) 1,810 ICU patients with severe sepsis or septic shock 20% albumin and crystalloid 903 Crystalloid solution 907 28- and 90-day mortality; organ dysfunction, LOS No difference in mortality or other outcomes
  1. N, number of patients; ICU, intensive care unit; HES, hydroxyethyl; AKI, acute kidney injury; RRT, renal replacement therapy; MV, mechanical ventilation; LOS, length of stay (ICU or hospital).